Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases

Thiolutin is a disulfide-containing antibiotic and anti-angiogenic compound produced by Streptomyces. Its biological targets are not known. We show that reduced thiolutin is a zinc chelator that inhibits the JAB1/MPN/Mov34 (JAMM) domain–containing metalloprotease Rpn11, a deubiquitinating enzyme of the 19S proteasome. Thiolutin also inhibits the JAMM metalloproteases Csn5, the deneddylase of the COP9 signalosome; AMSH, which regulates ubiquitin-dependent sorting of cell-surface receptors; and BRCC36, a K63-specific deubiquitinase of the BRCC36-containing isopeptidase complex and the BRCA1–BRCA2-containing complex. We provide evidence that other dithiolopyrrolones also function as inhibitors of JAMM metalloproteases

Interns overestimate the effectiveness of their hand-off communication

Theories from the psychology of communication may be applicable in understanding why hand-off communication is inherently problematic. The purpose of this study was to assess whether postcall pediatric interns can correctly estimate the patient care information and rationale received by on-call interns during hand-off communication. METHODS: Pediatric interns at the University of Chicago were interviewed about the hand-off. Postcall interns were asked to predict what on-call interns would report as the important pieces of information communicated during the hand-off about each patient, with accompanying rationale. Postcall interns also guessed on-call interns' rating of how well the hand-offs went. Then, on-call interns were asked to list the most important pieces of information for each patient that postcall interns communicated during the hand-off, with accompanying rationale. On-call interns also rated how well the hand-offs went. Interns had access to written hand-offs during the interviews. RESULTS: We conducted 52 interviews, which constituted 59% of eligible interviews. Seventy-two patients were discussed. The most important piece of information about a patient was not successfully communicated 60% of the time, despite the postcall intern's believing that it was communicated. Postcall and on-call interns did not agree on the rationales provided for 60% of items. In addition, an item was more likely to be effectively communicated when it was a to-do item (65%) or an item related to anticipatory guidance (69%) compared with a knowledge item (38%). Despite the lack of agreement on content and rationale of information communicated during hand-offs, peer ratings of hand-off quality were high. CONCLUSIONS: Pediatric interns overestimated the effectiveness of their hand-off communication. Theories from communication psychology suggest that miscommunication is caused by egocentric thought processes and a tendency for the speaker to overestimate the receiver's understanding. This study demonstrates that systematic causes of miscommunication may play a role in hand-off quality

The Improving Rural Cancer Outcomes Trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia.

BACKGROUND: Rural Australians have poorer survival for most common cancers, due partially to later diagnosis. Internationally, several initiatives to improve cancer outcomes have focused on earlier presentation to healthcare and timely diagnosis. We aimed to measure the effect of community-based symptom awareness and general practice-based educational interventions on the time to diagnosis in rural patients presenting with breast, prostate, colorectal or lung cancer in Western Australia. METHODS: 2 × 2 factorial cluster randomised controlled trial. Community Intervention: cancer symptom awareness campaign tailored for rural Australians. GP intervention: resource card with symptom risk assessment charts and local cancer referral pathways implemented through multiple academic detailing visits. Trial Area A received the community symptom awareness and Trial Area B acted as the community campaign control region. Within both Trial Areas general practices were randomised to the GP intervention or control. PRIMARY OUTCOME: total diagnostic interval (TDI). RESULTS: 1358 people with incident breast, prostate, colorectal or lung cancer were recruited. There were no significant differences in the median or ln mean TDI at either intervention level (community intervention vs control: median TDI 107.5 vs 92 days; ln mean difference 0.08 95% CI -0.06-0.23 P=0.27; GP intervention vs control: median TDI 97 vs 96.5 days; ln mean difference 0.004 95% CI -0.18-0.19 P=0.99). There were no significant differences in the TDI when analysed by factorial design, tumour group or sub-intervals of the TDI. CONCLUSIONS: This is the largest trial to test the effect of community campaign or GP interventions on timeliness of cancer diagnosis. We found no effect of either intervention. This may reflect limited dose of the interventions, or the limited duration of follow-up. Alternatively, these interventions do not have a measurable effect on time to cancer diagnosis

PIP-II Injector Test's Low Energy Beam Transport: Commissioning and Selected Measurements

The PIP2IT test accelerator is under construction at Fermilab. Its ion source and Low Energy Beam Transport (LEBT) in its initial (straight) configuration have been commissioned to full specification parameters. This paper introduces the LEBT design and summarizes the outcome of the commissioning activities.Comment: 11

Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy.

OBJECTIVE: This study aims to determine local treatment response and long-term survival outcomes in patients with localised muscle-invasive bladder cancer (MIBC) patients receiving neoadjuvant chemotherapy (NAC) using diffusion-weighted MRI (DWI) and apparent diffusion coefficient (ADC) analysis. METHODS: Patients with T2-T4aN0-3M0 bladder cancer suitable for NAC were recruited prospectively. DWI was performed prior to NAC and was repeated following NAC completion. Conventional response assessment was performed with cystoscopy and tumour site biopsy. Response was dichotomised into response (15.5% was associated with significant improvement in OS (HR, 0.40; 95% CI, 0.19-0.86; p=0.0179), bCSS (HR, 0.26; 95% CI, 0.08-0.82; p=0.0214), PFS (HR, 0.16; 95% CI, 0.05-0.48; p=0.0012), and time to cystectomy (HR, 0.19; 95% CI, 0.07-0.47; p=0.0004). CONCLUSIONS: Quantitative ADC analysis can successfully identify NAC response and improved long-term clinical outcomes. Multi-centre validation to assess reproducibility and repeatability is required before testing within clinical trials to inform MIBC treatment decision making. ADVANCES IN KNOWLEDGE: We successfully demonstrated that measured change in DWI can successfully identify NAC response and improved long-term survival outcomes

Leveraging SN Ia spectroscopic similarity to improve the measurement of H0H_0

Recent studies suggest spectroscopic differences explain a fraction of the variation in Type Ia supernova (SN Ia) luminosities after light-curve/color standardization. In this work, (i) we empirically characterize the variations of standardized SN Ia luminosities, and (ii) we use a spectroscopically inferred parameter, SIP, to improve the precision of SNe Ia along the distance ladder and the determination of the Hubble constant ($H_0$). First, we show that the \texttt{Pantheon+} covariance model modestly overestimates the uncertainty of standardized magnitudes by $\sim 7$%, in the parameter space used by the $\texttt{SH0ES}$ Team to measure $H_0$; accounting for this alone yields $H_0 = 73.01 \pm 0.92$ km s$^{-1}$ Mpc$^{-1}$. Furthermore, accounting for spectroscopic similarity between SNe~Ia on the distance ladder reduces their relative scatter to $\sim0.12$ mag per object (compared to $\sim 0.14$ mag previously). Combining these two findings in the model of SN covariance, we find an overall 14% reduction (to $\pm 0.85$km s$^{-1}$ Mpc$^{-1}$) of the uncertainty in the Hubble constant and a modest increase in its value. Including a budget for systematic uncertainties itemized by Riess et al. (2022a), we report an updated local Hubble constant with $\sim1.2$% uncertainty, $H_0 = 73.29 \pm 0.90$km s$^{-1}$ Mpc$^{-1}$. We conclude that spectroscopic differences among photometrically standardized SNe Ia do not explain the ``Hubble tension." Rather, accounting for such differences increases its significance, as the discrepancy against $\Lambda$CDM calibrated by the ${\it Planck}$ 2018 measurement rises to 5.7$\sigma$.Comment: 28 pages, 15 figures, accepted to JCA

Quantum resonances and decoherence for delta-kicked atoms

The quantum resonances occurring with delta-kicked atoms when the kicking period is an integer multiple of the half-Talbot time are analyzed in detail. Exact results about the momentum distribution at exact resonance are established, both in the case of totally coherent dynamics and in the case when decoherence is induced by Spontaneous Emission. A description of the dynamics when the kicking period is close to, but not exactly at resonance, is derived by means of a quasi-classical approximation where the detuning from exact resonance plays the role of the Planck constant. In this way scaling laws describing the shape of the resonant peaks are obtained. Such analytical results are supported by extensive numerical simulations, and explain some recent surprising experimental observations.Comment: 51 pages, 13 figures; KEYWORDS: quantum chaos, decoherence, kicked rotor, dynamical localization, atom optics; submitted to Nonlinearit

Widespread Expression of BORIS/CTCFL in Normal and Cancer Cells

BORIS (CTCFL) is the paralog of CTCF (CCCTC-binding factor; NM_006565), a ubiquitously expressed DNA-binding protein with diverse roles in gene expression and chromatin organisation. BORIS and CTCF have virtually identical zinc finger domains, yet display major differences in their respective C- and N-terminal regions. Unlike CTCF, BORIS expression has been reported only in the testis and certain malignancies, leading to its classification as a “cancer-testis” antigen. However, the expression pattern of BORIS is both a significant and unresolved question in the field of DNA binding proteins. Here, we identify BORIS in the cytoplasm and nucleus of a wide range of normal and cancer cells. We compare the localization of CTCF and BORIS in the nucleus and demonstrate enrichment of BORIS within the nucleolus, inside the nucleolin core structure and adjacent to fibrillarin in the dense fibrillar component. In contrast, CTCF is not enriched in the nucleolus. Live imaging of cells transiently transfected with GFP tagged BORIS confirmed the nucleolar accumulation of BORIS. While BORIS transcript levels are low compared to CTCF, its protein levels are readily detectable. These findings show that BORIS expression is more widespread than previously believed, and suggest a role for BORIS in nucleolar function